Biocon Pharma Limited Receives Health Canada Approval for Micafungin for Injection, USP, 50 MG and 100 MG

Biocon Pharma Limited, a subsidiary of Biocon Limited, today announced that it has received approval from Health Canada for micafungin for injection, USP, 50 mg and 100 mg. The approved product is indicated for use in adults and children four months and older for treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections; treatment of patients with esophageal candidiasis; and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

The approval will further strengthen Biocon's integrated biosimilars and generics portfolio.

Shares of Biocon Limited was last trading in BSE at Rs. 390.50 as compared to the previous close of Rs. 380.55. The total number of shares traded during the day was 606337 in over 12880 trades.

The stock hit an intraday high of Rs. 396.00 and intraday low of 348.05. The net turnover during the day was Rs. 235309872.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 Biotechnology HealthCanadaApproval Micafungin Injection